Ketanserin, a Novel 5-Hydroxytryptamine Antagonist: Monotherapy in Essential Hypertension.

British Journal of Clinical Pharmacology - United Kingdom
doi 10.1111/j.1365-2125.1983.tb04974.x
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Treatment of Hypertension With Ketanserin, a New Selective 5-Ht2 Receptor Antagonist.

BMJ
1982English

Ketanserin in Essential Hypertension: A Double-Blind, Placebo-Controlled Study.

Postgraduate Medical Journal
Medicine
1985English

Adequacy of Olmesartan Monotherapy Versus Cotherapy in Patients With Essential Hypertension

International Journal of Research in Pharmaceutical Sciences
ToxicologyPharmaceuticsPharmacology
2020English

5-Hydroxytryptamine

Postgraduate Medical Journal
Medicine
1958English

The Effect of a 5-Ht Antagonist, Ketanserin, on Blood Pressure, the Renin-Angiotensin System and Sympathoadrenal Function in Normal Man.

British Journal of Clinical Pharmacology
Pharmacology
1983English

Treatment Patterns Among Patients Prescribed Pde-5 Inhibitor Monotherapy for Pulmonary Hypertension

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Peroxisome Proliferator-Activated Receptor- Ameliorates Pulmonary Arterial Hypertension by Inhibiting 5-Hydroxytryptamine 2B Receptor

Hypertension
Internal Medicine
2012English

Robalzotan (NAD-299), a Novel Selective 5-Ht 1A Receptor Antagonist

CNS Drug Reviews
2006English

Effect of Fluvoxamine on 5-Hydroxytryptamine Uptake, Paroxetine Binding Sites and Ketanserin Binding Sites in the Japanese Monkey Brain and Platelets, in Vivo and in Vitro.

The Japanese Journal of Pharmacology
1996English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy